Blackpool CCG Medicines Optimisation

Blackpool CCG Medicines Optimisation

Medicines play an important part in promoting well-being, preventing ill-health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines Management can be defined in several ways:

The clinical, cost-effective, safe and secure handling of medicines
A system of processes and behaviours that determines how medicines are used by the NHS and patients
Enabling people to make the best possible use of medicines
Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s Medicines Management team on 01253 951306 or email blackpool.medicinesoptimisation@nhs.net


 

Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

NameSizeHits
28 Day Prescribing 0.3 MB95
Cannabis based medicinal products for pain 0.5 MB100
Clinical Need Low Priority Medicines - General 0.3 MB205
Clinical Need Soluble Analgesics 0.5 MB112
Clinical Need Thickeners Position Statement 0.3 MB75
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB71
Denosumab Position Statement 0.3 MB78
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB118
Edoxaban Position Statement 0.2 MB78
Emollients and Sunscreens 0.2 MB138
Free of Charge (FOC) Medicines schemes 0.3 MB70
Generic Biosimilar Medicines Position Statement 0.2 MB74
Generic Prescribing Guidelines 0.3 MB143
Glucose Monitoring Devices 0.5 MB113
Gluten Free Foodstuffs 0.2 MB89
Health Professionals e-cigarettes briefing 0.2 MB66
Holiday Medication 0.2 MB113
Liothyronine 0.2 MB69
Nutritional Supplements Post Bariatric Surgery 0.3 MB87
Ophthalmology Macular Pathways 1.1 MB78
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB103
Out of Area Prescribing 0.2 MB47
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB94
Position Statement Sip Feeds 0.4 MB79
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB71
Prescribing Vitamins And Minerals 0.3 MB72
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB60
Stoma Care Products - deodorants and air fresheners 0.4 MB86
Trans Anal Irrigation Devices 0.2 MB77
Zero Risk Schemes 0.3 MB65

Prescribing guidance

NameSizeHits
Axial-Spondyloarthritis-pathway-Version 37 KB60
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB75
Chronic Non-cancer Pain Guidelines 0.7 MB72
Colomycin prescribing information sheet Non CF indications. 0.2 MB58
Constipation-Pathway-Version 0.7 MB108
COPD guideline 0.6 MB48
Diabetes - Algorithm for antihyperglycaemic therapy in adults with type II Diabetes 0.6 MB72
Diabetes - BG meters and test strips Type-2-Diabetes 0.5 MB172
Diabetes - Glucagon Like Peptide Contract 0.2 MB83
Diabetes - Home Monitoring of Blood Glucose Levels Guidelines 0.3 MB75
Diabetes-self-management-contract 0.5 MB108
Edoxaban Prescribing Tip 68 KB114
Erectile-Dysfunction-Guideline-Version 1.0 MB90
Flash Glucose Monitoring policy - L&SC 0.2 MB24
Gastroenterology-Biologics-Pathway-Version 0.4 MB95
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB74
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB128
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB35
Headache Management Guideline for Adults 0.7 MB41
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB69
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB14
Interim Gender Dysphoria protocol 0.6 MB52
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB75
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB67
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB111
Neuropathic Pain Guidance (Version 1.2) 0.9 MB71
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB82
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB68
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB85
Primary Care Good Prescribing Guide 0.6 MB116
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB74
Psoriasis-LMMG-Biologic-and-High-Cost-Drug-Commissioning-Pathway-Version 0.8 MB90
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB85
RA-High-Cost-Drugs-Pathway-v 0.2 MB89
Restless Legs Syndrome guidelines 0.3 MB48
SIP Feeds 0.1 MB80
Trans female prescribing information sheet 0.2 MB9
Trans male prescribing information sheet 0.2 MB5
Wound care formulary 8.2 MB115

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Fencino (Fentanyl) – Started 1 October 2018
  • Firmagon (Degarelix) – Started 1 September 2016
  • Januvia (Sitagliptin)  – Started 1 September 2018
  • Lixiana (Edoxaban) – Started 1 October 2018
  • Seretide (Fluticasone / Salmeterol) – Started 1 January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started 1 October 2018
  • Clenil Modulite – Started 1 July 2019
  • Longtec (Oxycodone SR) – Started 1 July 2019
  • Sereflo – Started 1 June 2019
  • Xarelto (Rivaroxaban) – Started 1 July 2019

Last updated on 15 August 2019 at 11:01 by communications and engagement manager